Nadim Yared


CVRx Inc.



Any medical device company that lands venture financing in the current risk-averse climate has something to brag about. Given that, Nadim Yared of CVRx Inc. may be the king of the hill among start-up med-tech CEOs, after obtaining $113 million in debt and equity financing to support a Phase III clinical trial and commercialization of its Barostim NEO device—one of the nation’s biggest med-tech financings of 2016. Efforts to battle chronic heart failure with nerve stimulation devices, however, have a checkered past, and in the coming months investors will be focused on the results of a pivotal clinical trial for Barostim called BeAT-HF (short for baroreflex activation therapy for heart failure).